Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
OpenAI Nears Astra AI Model Launch With Safety Focus 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
OpenAI Rejects Apple Trade Secret Theft Claims 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Add as a preferred source on Google
CHESTERBROOK, Pa., March 14, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Oppenheimer & Company 28th Annual Healthcare Conference on Wednesday, March 21, 2018, at 2:45 p.m. EDT in New York, NY.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine) Injection for the management of moderate-to-severe acute pain. OLINVO has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
